



Proteomics International

LABORATORIES LTD

ASX Release
22 February 2022

ASX code: PIQ

PromarkerD completes 'pre-assessment' for Medicare rebate

- **Proteomics International has completed the 'pre-assessment' phase of its application to have PromarkerD included on the Australian Medicare Benefit Schedule (MBS)**
- **Inclusion on the schedule would see eligible patients receive a Medicare rebate for PromarkerD in Australia**
- **The Company will now submit a full application for review by the Medical Services Advisory Committee (MSAC)**
- **Receiving a MBS listing is a key milestone for commercialising the test in Australia**

Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) has completed the 'pre-assessment' phase of Australia's medical reimbursement system for PromarkerD, the world's first predictive diagnostic test for diabetic kidney disease.

The application lays the groundwork for the test to be added to the Medicare Benefit Schedule (MBS). Inclusion on the schedule would mean eligible patients receive a Medicare rebate for the PromarkerD test.

In Australia, the suitability of new medical services for public funding is appraised by the Medical Services Advisory Committee (MSAC). This independent, non-statutory committee advises the government on whether services should attract a Medicare rebate.

PromarkerD has cleared the 'pre-assessment' stage of the process, which includes a systematic review of clinical evidence and practice, an economic evaluation, and the proposed item descriptor and fee by a specialist sub-committee.

Proteomics International will now submit a full application for the 'assessment' stage of the process, which includes evaluation by a second sub-committee and consideration from the full MSAC. It is expected MSAC will meet in November 2022 to consider the proposal to include PromarkerD on the MBS, and may recommend, defer or reject the test for listing. The Company is also pursuing Therapeutic Goods Administration (TGA) approval for PromarkerD, which is a parallel and independent process, and the Company will provide updates as and when events occur on this front.

Proteomics International managing director Dr Richard Lipscombe said inclusion on the MBS was an important step to bring PromarkerD to the Australian market. *"If MSAC recommendation is secured, it will be a key milestone in commercialising PromarkerD in Australia. It means eligible patients are likely to receive Medicare rebate for the test,"* he said.

Dr Lipscombe said he was confident in the strong body of evidence for PromarkerD. *"We know the test is safe, it's effective and it significantly outperforms current standard-of-care tests for diabetic kidney disease. Our studies show PromarkerD will both improve patient quality of life and reduce overall costs to the health system, through fewer patients requiring dialysis and kidney transplants."*

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

Authorised by the Board of Proteomics International Laboratories Ltd (ASX:PIQ).

ENDS

About PromarkerD (www.PromarkerD.com)

Diabetic kidney disease (DKD) is a serious complication arising from diabetes which if unchecked can lead to dialysis or kidney transplant. PromarkerD is a prognostic test that can predict future kidney function decline in patients with type 2 diabetes and no existing DKD. The patented PromarkerD test system uses a simple blood test to detect a unique 'fingerprint' of the early onset of the disease by measuring three serum protein biomarkers, combined with three routinely available conventional clinical variables (age, HDL-cholesterol and estimated glomerular filtration rate (eGFR)). A cloud based algorithm integrates the results into a patient risk report. In clinical studies published in leading journals PromarkerD correctly predicted up to 86% of otherwise healthy diabetics who went on to develop diabetic kidney disease within four years. The PromarkerD test is CE Mark registered in the European Union.

Further information is available through the PromarkerD web portal.

To visit the PromarkerD virtual booth please see: www.PromarkerD.com/product

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Dirk van Dissel
Investor Relations & Corporate Advisor
Candour Advisory
T: +61 408 326 367
E: dirk@candouradvisory.com.au

Kyle Moss
Corporate Advisor
Euroz Hartleys
T: +61 8 9488 1400
E: kmoss@eurozhartleys.com

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com